Below you'll find a list of all posts that have been tagged as “life sciences”
A leading pharmaceutical company needed a validated, continuously updated view of the competitive landscape across lab, point-of-care, and self-test diagnostics. Sedulo’s program combined landscape analysis, ongoing monitoring, and primary intelligence to support confident D2C strategy and expansion decisions.
A leading pharmaceutical company needed a validated, continuously updated view of the competitive landscape across lab, point-of-care, and self-test diagnostics. Sedulo’s program combined landscape analysis, ongoing monitoring, and primary intelligence to support confident D2C strategy and expansion decisions.
A major oncology congress means something very different to a team supporting a Phase 2 asset than it does to a team twelve months from launch. The event is the same. The therapeutic area may be the same. But what the CI function needs to extract from it, what counts as high-priority intelligence, what gets documented with the most care, …
Every major pharmaceutical and biotech company at a medical congress has made a series of deliberate decisions before a single attendee walks through the exhibit hall doors. How large a footprint to take. Where on the floor to position it. What messaging to put on the largest visible surface. Which data to feature. What materials to hand to every HCP …
Most pharma CI teams attend the major congresses. Few are structured to capture everything those congresses offer. This post breaks down the five most common intelligence gaps, and what a well-designed coverage program does to close them.
A pharmaceutical company needed more than a snapshot of competitor sales forces. Sedulo designed a continuous oncology intelligence program that tracked how seven key competitors were structuring, scaling, and deploying commercial resources, delivering the early signals needed to sharpen share-of-voice strategy and commercial planning.
Scientific and medical conferences are among the most intelligence-rich environments in pharma, but most organizations capture only a fraction of what’s available. This guide breaks down what a structured conference coverage program looks like and how to turn congress attendance into actionable competitive intelligence.
The life sciences organizations that consistently make better decisions aren’t necessarily the ones with the most data, they’re the ones that have built competitive intelligence into the fabric of how they plan and act. Drawing on primary research, expert interviews, and Sedulo Group’s Annual Life Sciences CI Survey, this post outlines five practical recommendations for elevating CI from a reporting function to a true driver of strategic impact.
A competitive early warning system in life sciences is a structured monitoring model that identifies, validates, and interprets competitor and market signals so teams can anticipate strategic shifts before they affect clinical, commercial, regulatory, or portfolio decisions. Why Traditional Competitor Monitoring Is No Longer Enough Life sciences companies are working in one of the most crowded competitive environments in the …
A breakdown of the most important Pharma CI Europe 2026 insights, from evolving competitive dynamics to the strategic shifts redefining pharma launch and commercialization.
